LONDON – Roche Holding AG has pulled the plug on its spinal muscular atrophy (SMA) drug, olesoxime (RG-6083), just as it was expected to start a phase III trial, blaming among other difficulties the higher hurdle set by Biogen Inc.'s Spinraza (nusinersen), for how effective a new treatment needs to be.